Filtered By:
Specialty: Cardiology
Drug: Vytorin
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 100 results found since Jan 2013.
Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome
This study was a prospective, randomized controlled study. A total of 136 patients with extremely high-risk ACS with LDL-C ≥ 3.0 mmol/L after percutaneous coronary intervention (PCI) treatment were randomly assigned 1:1 to the control group (atorvastatin 40 mg/day and ezetimibe 10 mg/day) or the evolocumab group (evolocumab 140 mg every 2 weeks combined with atorvastatin 40 mg/day and ezetimibe 10 mg/day). We compared the blood lipid profiles, major adverse cardiovascular events (MACEs), and adverse reactions. MACEs included cardiogenic death, nonfatal myocardial infarction, nonfatal stroke, and readmission due to angina...
Source: International Heart Journal - July 13, 2022 Category: Cardiology Authors: Yan Hao Yu-Lin Yang Yong-Chao Wang Jian Li Source Type: research
Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease
Prog Cardiovasc Dis. 2022 May 19:S0033-0620(22)00046-9. doi: 10.1016/j.pcad.2022.05.003. Online ahead of print.ABSTRACTInternational guidelines strongly recommend statins alone or in combination with other lipid-lowering agents to lower low-density lipoprotein cholesterol (LDL-C) levels for patients with asymptomatic/symptomatic carotid stenosis (AsxCS/SCS). Lowering LDL-C levels is associated with significant reductions in transient ischemic attack, stroke, cardiovascular (CV) event and death rates. The aim of this multi-disciplinary overview is to summarize the benefits and risks associated with lowering LDL-C with stati...
Source: Atherosclerosis - May 23, 2022 Category: Cardiology Authors: Kosmas I Paraskevas Peter Gloviczki Pier Luigi Antignani Anthony J Comerota Alan Dardik Alun H Davies Hans-Henning Eckstein Gianluca Faggioli Jose Fernandes E Fernandes Gustav Fraedrich George Geroulakos Jonathan Golledge Ajay Gupta Victor S Gurevich Arka Source Type: research
Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis
Conclusions and RelevanceThis study identified the price at which inclisiran is cost effective for the US health system, at generally accepted willingness-to-pay thresholds.
Source: American Journal of Cardiovascular Drugs - May 21, 2022 Category: Cardiology Source Type: research
